Abata Therapeutics Receives FDA Fast Track Designation for ABA-101 for the Treatment of Progressive Multiple Sclerosis
August 22, 2024 07:00 ET
|
Abata
Abata Therapeutics Receives FDA Fast Track Designation for ABA-101 for the Treatment of Progressive Multiple Sclerosis
Multiple Sclerosis Market Set to Reach USD 33.57 Billion by 2032, Growing at a CAGR of 5.4% | Polaris Market Research (PMR)
August 19, 2024 08:25 ET
|
Polaris Market Research & Consulting LLP
New York, USA, Aug. 19, 2024 (GLOBE NEWSWIRE) -- Market Overview: The multiple sclerosis market was estimated at USD 21.04 billion in 2023. The market valuation is expected to be USD 33.57 billion...
Autoinjectors Market Size to Hit USD 3.8 Billion Milestone by 2034 with 16.2% CAGR Growth | Exclusive Report by Transparency Market Research, Inc.
August 19, 2024 07:25 ET
|
Transparency Market Research
Wilmington, Delaware, United States, Transparency Market Research, Inc., Aug. 19, 2024 (GLOBE NEWSWIRE) -- The autoinjectors market (自動注射器市場) value was US$ 1.0 Billion in 2022 and is anticipated to...
Tiziana Life Sciences Appoints New Chief Executive Officer
August 19, 2024 07:00 ET
|
Tiziana Life Sciences Ltd.
NEW YORK, Aug. 19, 2024 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with...
Abata Therapeutics Announces Strategic Investment from Bristol Myers Squibb Supporting Advancement of its Treg Cell Therapy Pipeline into Clinical Development
August 15, 2024 07:00 ET
|
Abata
Abata Therapeutics Announces Strategic Investment from Bristol Myers Squibb Supporting Advancement of its Treg Cell Therapy Pipeline
Medsenic reçoit l'intention de délivrer un brevet européen clé de l'OEB, précieux pour le développement thérapeutique du trioxyde d'arsenic dans la sclérose en plaques récurrente-rémittente.
August 14, 2024 01:00 ET
|
BioSenic
INFORMATION PRIVILEGIEE Le médicament de Medsenic, le trioxyde d'arsenic, peut maintenant être étudié pour le traitement de la sclérose en plaques par des cycles répétés d'administration par de...
Medsenic receives the intention to grant a key European patent from EPO, valuable for the therapeutic development of arsenic trioxide in relapsing-remitting multiple sclerosis
August 14, 2024 01:00 ET
|
BioSenic
INSIDE INFORMATION Medsenic's experimental drug, arsenic trioxide, can now be investigated for the treatment of multiple sclerosis through repeated cycles of administration by multiple routes,...
Tiziana Life Sciences Granted FDA Fast Track Designation
July 24, 2024 07:00 ET
|
Tiziana Life Sciences Ltd.
NEW YORK, July 24, 2024 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with...
Abata Therapeutics Announces FDA Clearance of Investigational New Drug Application for Clinical Evaluation of ABA-101 in Progressive Multiple Sclerosis
July 09, 2024 06:00 ET
|
Abata
Abata Therapeutics Announces FDA Clearance of Investigational New Drug Application for Clinical Evaluation of ABA-101 in Progressive Multiple Sclerosis
Courage in the Ring: MS Patient Fights for a Cure
July 08, 2024 09:00 ET
|
London Health Sciences Foundation
An MS patient battles for a cure in a boxing fundraiser aimed at raising funds for the MS Clinic in London, Ontario.